Federal documents show he disagreed with conclusions the benefits outweighed the risk of side effects, which are rare.

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Moderna Inc. said its experimental flu shot met its goal in a late-stage trial, clearing the path for its broader strategy of ...

An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for COVID-19 combination ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and ...

The Moderna vaccine is 94.5% effective against coronavirus, according to early data released Monday by the company, making it the second vaccine in the United States to have a stunningly high ...

Moderna has received nearly $2.5 billion from U.S. taxpayers to develop, manufacture and distribute its vaccine; while Pfizer/BioNTech has been promised just under $2 billion for manufacturing and ...

Moderna, a Cambridge, Massachusetts-based biotechnology company, developed a COVID-19 vaccine, mRNA-1273, that was authorized Friday. How effective are the candidate vaccines, and what does that mean?

Moderna, the maker of one of three COVID-19 vaccines currently authorized for use in the U.S., announced Tuesday it will start testing its vaccine on children as young as 6 months old.. The move ...

Moderna announced on Nov. 16 that a preliminary analysis showed its experimental vaccine was nearly 95% effective in preventing the novel coronavirus.